Amarin Co. plc (NASDAQ:AMRN) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 10,457,742 shares, a growth of 45.3% from the August 15th total of 7,198,761 shares. Currently, 3.6% of the company’s stock are short sold. Based on an average trading volume of 3,509,964 shares, the days-to-cover ratio is presently 3.0 days.

A number of research firms have commented on AMRN. Cantor Fitzgerald set a $10.00 price objective on shares of Amarin and gave the company a “buy” rating in a research note on Tuesday, June 12th. ValuEngine upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research note on Thursday, May 31st. BidaskClub upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, May 30th. Finally, Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.00.

NASDAQ AMRN opened at $2.94 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.13 and a debt-to-equity ratio of -1.25. The firm has a market capitalization of $932.49 million, a price-to-earnings ratio of -11.72 and a beta of 0.95. Amarin has a one year low of $2.35 and a one year high of $4.60.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $52.64 million for the quarter, compared to the consensus estimate of $54.88 million. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS. equities analysts anticipate that Amarin will post -0.42 earnings per share for the current year.

In related news, General Counsel Joseph T. Kennedy sold 26,942 shares of Amarin stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $3.00, for a total transaction of $80,826.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 4.08% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC increased its stake in shares of Amarin by 81.8% during the first quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 28,929 shares during the period. DRW Securities LLC increased its stake in shares of Amarin by 45.1% during the first quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 25,000 shares during the period. Claraphi Advisory Network LLC increased its stake in shares of Amarin by 637.3% during the first quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 73,738 shares during the period. TD Asset Management Inc. increased its stake in shares of Amarin by 54.4% during the second quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock worth $415,000 after acquiring an additional 47,300 shares during the period. Finally, GSA Capital Partners LLP increased its stake in shares of Amarin by 66.3% during the second quarter. GSA Capital Partners LLP now owns 162,800 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 64,900 shares during the period. Institutional investors own 38.28% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: Stock Symbols and CUSIP Explained

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.